← Back to Search

Tyrosine Kinase Inhibitor

Cabozantinib for Adrenocortical Cancer

Phase 2
Waitlist Available
Led By Mouhammed A Habra
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 4 months
Awards & highlights

Study Summary

This trial studies cabozantinib for treating patients with adrenal cortex cancer that has spread and cannot be removed by surgery.

Who is the study for?
This trial is for adults with advanced or metastatic adrenocortical carcinoma that can't be surgically removed. Participants must understand the study, agree to use contraception, have a certain level of physical fitness (ECOG 0-2), and not be pregnant. They should have recovered from previous treatments and have a life expectancy of at least 3 months.Check my eligibility
What is being tested?
The trial is testing Cabozantinib's effectiveness on patients with inoperable adrenal cortex cancer that has spread. It involves monitoring how the drug affects tumor growth by blocking enzymes needed for cell growth, alongside pharmacokinetic and pharmacogenomic studies.See study design
What are the potential side effects?
Cabozantinib may cause side effects such as fatigue, high blood pressure, hand-foot skin reactions, gastrointestinal symptoms like diarrhea and nausea, abnormal liver enzyme levels, decreased appetite and weight loss.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival (PFS) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Secondary outcome measures
Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE)
Overall response rate (ORR) as defined by RECIST 1.1 criteria
Overall survival (OS) as defined by RECIST 1.1 criteria

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (cabozantinib)Experimental Treatment3 Interventions
Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1080

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,763 Total Patients Enrolled
Mouhammed A HabraPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
240 Total Patients Enrolled

Media Library

Cabozantinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03370718 — Phase 2
Adrenal Cancer Research Study Groups: Treatment (cabozantinib)
Adrenal Cancer Clinical Trial 2023: Cabozantinib Highlights & Side Effects. Trial Name: NCT03370718 — Phase 2
Cabozantinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03370718 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Cabozantinib received regulatory clearance from the FDA?

"Despite there being no solid proof of its efficacy, cabozantinib's safety has been confirmed to a degree, thus it received an assessment score of 2."

Answered by AI

To what extent have other investigations been conducted on Cabozantinib?

"At present, the number of clinical investigations into cabozantinib stands at 109 with 11 in Phase 3. Despite being concentrated in Cordoba and Calabria, these trials are spread across 6848 locations worldwide."

Answered by AI

Is this an experimental medical trial?

"Since 2012, Cabozantinib has undergone extensive research. The original trial was funded by Exelixis and involved 86 patients to be approved for Phase 2 treatment. Over the past decade 109 studies have been conducted across 45 different countries in 1315 cities."

Answered by AI

Is it possible for volunteers to join the research endeavor at present?

"The information on clinicaltrials.gov reveals that this medical trial is no longer recruiting patients; the initial posting was back in February of 2018, and it has not been updated since April of 2022. Despite this, there are currently 2578 other trials actively accepting participants."

Answered by AI

What is the enrollment capacity for this clinical trial?

"This trial has concluded its recruitment phase and is no longer actively seeking participants. The research was initially posted on February 26th, 2018 but had its last revision made in April 29th 2022. If you are looking for alternative studies, 2469 trials related to the adrenal cortex have open roles while 109 clinical trials require people taking Cabozantinib."

Answered by AI

What disease states is Cabozantinib employed to combat?

"Cabozantinib is traditionally administered to those who have previously taken anti-vegf medication. Additionally, it can be helpful in managing advanced renal cell carcinoma (ARCC), adrenal medulla, and high risk cases."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
2018. "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03370718.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top